Live Online Conference: The Impurities Forum Part II - Nitrosamines and other Mutagenic Impurities

Live Online Conference: The Impurities Forum Part II - Nitrosamines and other Mutagenic Impurities

Course No 18994

This course is part of the GMP Certification Programme "ECA Certified Quality Control Manager". Learn more.

All times mentioned are CET

Costs

ECA-Member*: EUR 890,--
Regular Fee*: EUR 1090,--
EU/GMP Inspectorates*: EUR 545,--
APIC Member Discount*: EUR 990,--

(All prices excl. VAT)

* payable by credit card American Express Visa Mastercard

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Jürgen Martin, Martin-Consulting
Dr Corina Nachtsheim,  Quality Assessor, Germany
Dr Ulrich Rose, EDQM, France
Dr Andrew Teasdale, Astra Zeneca, UK

Objectives

In Part II of the Impurities Forum the relevant aspects of root cause analysis and risk assessment with respect to potential Nitrosamine contamination in drug substances and drug products will be discussed. You will hear what you need to know about the required risk assessments for medicinal products containing chemically synthesized APIs. In particular you will learn
  •  which root causes for Nitrosamine Impurities should be considered,
  •  which practical approaches can be applied to assess the risks related to potential Nitrosamine contamination,
  •  which safety aspects need to be considered regarding Nitrosamine Impurities in drug products,
  •  which regulatory actions are to be taken in case of Nitrosamine Impurities and what authorities expect in these cases.
You will get advice from industry experts on how to cope with the challenge of performing risk assessments. Furthermore a representative of the EDQM will inform you about the European Pharmacopoeia activities (policy) on mutagenic impurities with focus on Nitrosamines.

Background

Mutagenic substances as impurities in drug substances or drug products are of big concern as they have the potential to alter or damage human DNA. Among these species Nitrosamines and elemental impurities have triggered various regulatory activities and initiatives. Since September 2019 Marketing Authorisation Holders are requested to evaluate the risk of the presence of Nitrosamine impurities in human medicinal products containing chemically synthesised APIs. In case of a contamination with Nitrosamines MAHs are requested to file a variation application. All regulatory activities with regard to such cases have to be completed within a 3 years period (end of March 2022). The ICH Q3D Guideline for Elemental Impurities was published as Step 4 document and has meanwhile been revised twice, regarding Cadmium Inhalation PDE and cutaneous and transdermal products.

Target Group

The Live Online Conference addresses all personnel involved in development of drug substances and drug products from scientific staff to laboratory heads involved in R&D. The needs of Laboratory Managers, Supervisors and Analysts in pharmaceutical quality assurance and quality control departments will also be covered. This event will also address regulatory requirements and hence is applicable to people working in the regulatory affairs area.

Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.

At http://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in.  Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programme

European Pharmacopoeia Activities on Nitrosamines and other Mutagenic Impurities
  • Ph. Eur. General policy on DNA reactive impurities
  • Control of Nitrosamines in Ph. Eur.
  • Changes in individual and general monographs following the Sartan case
  • New general chapter on control of nitrosamines
Root Causes for Nitrosamine Impurities and Other Mutagenic Impurities – Practical Approaches to Assess the Risks
  • Development of a systematic risk-based approach
  • Key factors and the development of a decision tree
  • API
  • Drug Product
  • Packaging
Mutagenic Impurities Introduced from Supply Chains Processes
  • APIs, excipients, packaging materials impacting the purity Profile
  • Process mapping and evaluation of supply chain processes
  • Risk measurement and evaluation of process steps according to ICHQ9
  • Vendor audits, vendor complaint tracking and monitoring programs
  • Risk-based approach for supplier quality evaluation
  • Testing strategies
Workshop:
Conducting a Risk Assessment
In this Workshop the participants will work on several case studies and perform a risk assessment for different scenarios taking into account e.g. manufacturing equipment, dosage form of the drug product etc.

Nitrosamines and Other Genotoxic Impurities – Authorities Expectations and Dossier Requirements
  • The assessor’s approach: principles of toxicological assessment
  • Structural alerts
  • Limits and Permitted Daily Exposure
  • The ALARP principle
  • Examples of low daily dose drug substances
  • Impurities derived from alkylating agents (mesilate, besilate, tosilate, diisothionate); examples
  • Nitrosamines – the Valsartan case
  • Potential mutagenic residual solvents
  • Impurities derived from metal catalysts

Go back

GMP Conferences by Topics